The ROMP: A Powerful Approach to Synthesize Novel pH-Sensitive Nanoparticles for Tumor Therapy.
asbestos
cancer
epigenetic
histone deacetylases
inhibitors
nanoparticles
ring-opening metathesis polymerization
Journal
Biomolecules
ISSN: 2218-273X
Titre abrégé: Biomolecules
Pays: Switzerland
ID NLM: 101596414
Informations de publication
Date de publication:
12 02 2019
12 02 2019
Historique:
received:
29
11
2018
revised:
19
12
2018
accepted:
11
02
2019
entrez:
15
2
2019
pubmed:
15
2
2019
medline:
31
8
2019
Statut:
epublish
Résumé
Fast clearance, metabolism, and systemic toxicity are major limits for the clinical use of anti-cancer drugs. Histone deacetylase inhibitors (HDACi) present these defects, despite displaying promising anti-tumor properties on tumor cells in vitro and in in vivo models of cancer. The specific delivery of anti-cancer drugs into the tumor should improve their clinical benefit by limiting systemic toxicity and by increasing the anti-tumor effect. This paper deals with the synthesis of the polymeric nanoparticle platform, which was produced by Ring-Opening Metathesis Polymerization (ROMP), able to release anti-cancer drugs in dispersion, such as histone deacetylase inhibitors, into mesothelioma tumors. The core-shell nanoparticles (NPs) have stealth properties due to their poly(ethylene oxide) shell and can be viewed as universal nano-carriers on which any alkyne-modified anti-cancer molecule can be grafted by click chemistry. A cleavage reaction of the chemical bond between NPs and drugs through the contact of NPs with a medium presenting an acidic pH, which is typically a cancer tumor environment or an acidic intracellular compartment, induces a controlled release of the bioactive molecule in its native form. In our in vivo syngeneic model of mesothelioma, a highly selective accumulation of the particles in the tumor was obtained. The release of the drugs led to an 80% reduction of tumor weight for the best compound without toxicity. Our work demonstrates that the use of theranostic nanovectors leads to an optimized delivery of epigenetic inhibitors in tumors, which improves their anti-tumor properties in vivo.
Identifiants
pubmed: 30759891
pii: biom9020060
doi: 10.3390/biom9020060
pmc: PMC6406258
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
Drug Carriers
0
Histone Deacetylase Inhibitors
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
Nat Rev Drug Discov. 2012 Apr 13;11(5):384-400
pubmed: 22498752
Eur J Pharm Biopharm. 2013 Nov;85(3 Pt B):862-72
pubmed: 23537575
Angew Chem Int Ed Engl. 2018 Dec 21;57(52):17048-17052
pubmed: 30387923
J Pharm Sci. 2012 Oct;101(10):3787-98
pubmed: 22806441
Expert Opin Investig Drugs. 2007 Jul;16(7):1111-20
pubmed: 17594194
Expert Rev Anticancer Ther. 2010 Jul;10(7):997-1008
pubmed: 20645688
Nanomedicine (Lond). 2017 Jan;12(1):43-58
pubmed: 27879153
Drug Deliv. 2016 May;23(4):1335-43
pubmed: 25547270
Nanomedicine. 2017 Apr;13(3):885-896
pubmed: 27993720
Drugs. 2014 Sep;74(13):1543-54
pubmed: 25134672
Carbohydr Polym. 2014 Dec 19;114:407-15
pubmed: 25263908
Biomacromolecules. 2013 Jul 8;14(7):2396-402
pubmed: 23731363
Biomed Pharmacother. 2014 Sep;68(7):865-71
pubmed: 25107842
Oncotarget. 2017 Feb 28;8(9):14925-14940
pubmed: 28122339
Biomacromolecules. 2014 Dec 8;15(12):4534-43
pubmed: 25333409
Mater Sci Eng C Mater Biol Appl. 2015 Jun;51:362-8
pubmed: 25842146
Oncotarget. 2014 Jun 30;5(12):4504-15
pubmed: 24980825
Theranostics. 2016 Mar 25;6(6):795-807
pubmed: 27162550
Curr Cancer Drug Targets. 2011 Oct;11(8):919-28
pubmed: 21762083
J Natl Cancer Inst. 2015 Jun 01;107(6):djv165
pubmed: 26032612
Pharm Res. 2014 Aug;31(8):1978-88
pubmed: 24562809
J Nanobiotechnology. 2015 Sep 26;13:60
pubmed: 26410576
J Pharm Pharm Sci. 2014;17(2):231-47
pubmed: 24934552
AAPS PharmSciTech. 2018 Feb;19(2):634-647
pubmed: 28948528
Eur J Med Chem. 2015 May 5;95:369-76
pubmed: 25827403
Biomaterials. 2015 May;51:208-215
pubmed: 25771011
J Control Release. 2017 Nov 28;266:36-46
pubmed: 28893609
Jpn J Pharmacol. 1986 Jun;41(2):163-71
pubmed: 2427761
Eur Respir J. 2011 Nov;38(5):1105-16
pubmed: 21540307
Biomaterials. 2015 Oct;67:183-93
pubmed: 26218744
Int J Nanomedicine. 2016 Nov 11;11:6003-6022
pubmed: 27956831
Adv Drug Deliv Rev. 2015 Aug 30;91:3-6
pubmed: 25579058
Nanomedicine. 2013 Nov;9(8):1124-34
pubmed: 23764660
Cancer Manag Res. 2011;3:117-41
pubmed: 21625397
J Med Chem. 2009 May 14;52(9):3112-5
pubmed: 19385600